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Abstract
Introduction
•Major depressive disorder, depression, and dysthymia are 
often overlooked and undertreated conditions in the primary 
care field. This exists for a variety of reasons: social stigma, 
provider experience, concerns over medication side-effects, 
and cost of treatment, to name a few. Considering that in 
very many cases treatment of depression can be the 
difference between life and death for a patient, using every 
tool available seems imperative. Dehydroepiandrosterone 
and its sulphate ester (DHEA(-S)), a physiological marker 
and predictor for depression, especially in the elderly, is 
established despite some conflicting studies. The purpose of 
this paper is to ascertain if DHEA supplementation is a 
viable option for the treatment of depression in comparison 
to current standards of treatment with selective serotonin 
reuptake inhibitors (SSRIs) and selective serotonin and 
norepinephrine reuptake inhibitors (SNRIs), especially 
considering DHEA’s low cost and low side effect profile.
Research Question
Literature Review
Applicability to Clinical 
Practice
Discussion
• The presented data seem conclusive about the life-span 
and gender changes of DHEA and DHEA-S—that DHEA 
declines with age after peaking in our twenties, and typically 
men have more serum DHEA than women. However, 
attempts to correlate the existing data to depression, risk of 
depression, severity of symptoms, and remission of 
symptoms are less clear. Though, a trend among many 
smaller, under-powered studies is emerging: i.e. that lower 
DHEA is associated with risk of depression in the elderly, 
that a lower DHEA response to depression is associated with 
worse, or intractable depression, that higher levels of DHEA 
are protective against, or might signal remission of 
depression.
• Data suggests a mechanism to hormonally correct 
depression by raising levels of DHEA, but that impairment 
by physiologically low levels of DHEA, or low levels due to 
advanced age, might hinder this mechanism. Bolstering this 
idea is evidence that when depression is treated even with 
SSRIs and SNRIs, serum DHEA rises (Hough et al., 2017). 
The limits of this response appear to be personal and highly 
variable as no dose response mechanism for DHEA and 
depression has been identified by the literature. Specifically, 
Bloch et al. (1999) and Schmidt et al. (2005) found no 
increasing benefits with doses as high as 400 mg, whereas 
other studies only tested—and had success with—doses as 
high as 90 mg.
Dehydroepiandrosterone (DHEA) and its sulfated ester 
(DHEA-S) are important pre-hormones that also have 
direct neurohormonal effects on the central nervous 
system. Over the last twenty years, data have revealed that 
serum DHEA peaks in a person’s mid-20s and steadily 
declines throughout their lifetime. In addition, women tend 
to have lower values than men. This is of note because 
lower serum values tend to be correlated with increased 
risk of depression, worse depressive symptoms, and 
increased risk of relapse into depression. A review of 
literature concerning DHEA’s age related values, its 
association with depression, and its use in the treatment of 
depression was performed. It was found that 
supplementation with DHEA appears to alleviate the 
symptoms of depression even though a dose-response 
relationship nor a clear mechanism have been established. 
For providers who choose to use DHEA to alleviate the 
symptoms of depression, they should consider that even 
the best studies concerning its effectiveness are 
underpowered, it lacks FDA approval, and, if given as a 
supplement, may lack any active ingredient. Despite those 
warnings, the AAPA, CANMAT, and Dynamed all agree 
that evidence exists as to its efficacy.
• For patients older than 30 who have major depression, 
depressive symptoms, or depressive episodes, does 
supplementation with DHEA improve symptoms or lessen 
episodes of depression?
•Bloch, Schmidt, Danaceau, Adams, & Rubinow (1999) was 
one of the first double blind, randomized, placebo-controlled 
studies of the effect of DHEA administration on the effects 
of depression. Though statistically significant reductions in 
depressive indexes as well as in itemized indicators of 
depression were demonstrated with promising p values—
many at 0.01—the study is likely underpowered. Because the 
ANOVA data have been withheld, the effect size cannot be 
calculated; however, because this study only has an N of 15 
participants, the effect size to reach a power of 0.8 would 
need to be quite large. Bloch et al.’s colleagues Schmidt et al. 
(2005) attempted to recreate and expound on some of the 
findings of Bloch et al. with larger N and with varying doses. 
Schmidt et al.’s study found similar confidence values in 
their double-blind, randomized, placebo-controlled study 
across indicators and indexes of depression; though, this time 
with an N of 46, the power of successive studies are 
growing. Differing in Schmidt et al.’s study were doses 
increasing up to 450 mg with washout periods in between. 
Finding a dose response relationship between DHEA and 
depression would have further cemented DHEA’s 
effectiveness in treating depression; however, this link was 
not established. It is not until Piexto, Cheda, Nardi, Veras, & 
Cardoso (2014) that we see a meta-analysis of many of the 
existing, albeit underpowered, studies deliver consistent 
results. Though Piexto et al. (2014) did not attempt to group 
studies providing a single large N value due to differing 
methodologies between studies, the consistency of results is 
beginning to suggest that DHEA is effective in the treatment 
of depression despite all studies being likely underpowered.
• There is agreement among AAPA (Slawson, 2005), 
CANMAT (Ravindran et al., 2016), and Dynamed (2018) 
that exogenous DHEA may be useful in the treatment of 
depression. However, the lack of powerful studies in the data 
leaves us with a few questions yet about its best practice use. 
What dose does the literature support? What serum level is 
important? Is it effective only as a sole agent? Are its side 
effects acceptable? 
• Because there has yet to be a dose-response relationship 
established, starting with the lowest tested dose—30 mg—
and titrating up to the largest dose—400 mg (Piexto et al. 
2014)—is reasonable. Indeed, because of the lack of dose-
response relationship any, even the lowest, prescription of 
DHEA might prove effective. Furthermore, because of a lack 
of a dose-response relationship, in DHEA therapy for 
depression we are not attempting to achieve an effective 
serum level and if symptomatic alleviation is our goal, serum 
testing is moot. At least one study (Hough et al., 2018) has 
recommended that DHEA might be efficacious as co-therapy 
for treatment of depression.
• Best practice for prescriptions of DHEA might include 
prescribing as a sole agent for mild to moderate depression 
or when the patient finds the side effects of other therapy 
intolerable. Its use as a sole agent might be more effective in 
elderly men. It could be prescribed as co-therapy with more 
traditional antidepressants. Above all, treatment with DHEA 
should be done so with its particular side effects in mind, as 
well as the added risk of increased suicidality. Also of key 
clinical importance is DHEA’s lack of FDA approval for the 
treatment of depression, meaning every provider who 
prescribes DHEA for depression should be prepared to 
plainly state why they did not treat with FDA approved 
drugs. Finally, if a provider chooses to treat depression with 
DHEA they should note that while it is available over the 
counter as a supplement, only pharmaceutical DHEA is sure 
to contain DHEA; supplements routinely fail to demonstrate 
they contain any claimed active ingredient. With this in 
mind, the aim of this paper was to provide another tool for 
the primary care provider to manage the sometimes life-
threatening scourge of depression.Statement of the Problem
•Primary care providers who do choose to treat major 
depressive disorder, depression, and dysthymia seem to limit 
their pharmacological options to only the SSRIs, SNRIs, and 
other prescription-only antidepressants. DHEA’s low side 
effect profile, comparatively low cost, and availability may 
make it an ideal adjunct or replacement to current therapy. 
But is it effective? Because of DHEA’s known age related 
decline, this paper will focus on adults only.
References
Forest plots for differences between DHEA-S levels in patients with depression and 
without.
Qiang, H., Zhang, S., Liu, F., Zhang, Y., Zhu, D., & Zang, Y. (2015). Clinical 
significance of decreased protein expression of dehydroepiandrosterone sulfate in the 
development of depression: A meta-analysis. Journal of Affective Disorders, 174, 416-
423. https://dx.doi.org/10.1016/j.jad.2014.11.051
Meta-analysis results of exogenous DHEA administration in depressed 
populations.
Peixoto, C., Cheda, J., Nardi, A., Veras, A., & Cardoso, A. (2014). The effects of 
dehydroepiandrosterone (DHEA) in the treatment of depression and depressive 
symptoms in other psychiatric and medical illnesses: A systematic review. Current 
Drug Targets, 15, 901-914. 
https://dx.doi.org/10.2174/1389450115666140717111116
Bloch, M., Schmidt, P., Danaceau, M., Adams, L., & Rubinow, D. (1999). 
Dehydroepiandrosterone treatment of midlife dysthymia. Society of 
Biological Psychiatry, 45, 1533-1541. 
https://dx.doi.org/10.1016/S0006-3223(99)00066-9
DynaMed Plus. (2018, August 9). Depression alternative treatments. 
Ipswich, MA: EBSCO Information Services. Retrieved from 
http://www.dynamed.com/topics/dmp~AN~T474293/Depression-
alternative-treatments#Dehydroepiandrosterone
Hough, C., Lindqvist, D., Epel, E., Denis, M., Reus, V., Bersani, F.,… 
Mellon, S. (2017). Higher serum DHEA concentrations before and 
after SSRI treatment are associated with remission of major 
depression. Psychoneuroendocrinology, 77, 122-130. 
https://dx.doi.org/10.1016/j.psyneuen.2016.11.035
Peixoto, C., Cheda, J., Nardi, A., Veras, A., & Cardoso, A. (2014). The 
effects of dehydroepiandrosterone (DHEA) in the treatment of 
depression and depressive symptoms in other psychiatric and 
medical illnesses: A systematic review. Current Drug Targets, 15, 
901-914. https://dx.doi.org/10.2174/1389450115666140717111116
Qiang, H., Zhang, S., Liu, F., Zhang, Y., Zhu, D., & Zang, Y. (2015). Clinical 
significance of decreased protein expression of dehydroepiandrosterone 
sulfate in the development of depression: A meta-analysis. Journal of 
Affective Disorders, 174, 416-423. 
https://dx.doi.org/10.1016/j.jad.2014.11.051
Ravindran, A., et al. (2016). Canadian network for mood and anxiety 
treatments (CANMAT) 2016 clinical guidelines for the management of 
adults with major depressive disorder: Section 5. Complementary and 
alternative medicine treatments. The Canadian Journal of 
Psychiatry/Le Revue Canadienne de Psychiatrie, 61(9), 576-587. 
https://dx.doi.org/10.1177/0706743716660290
Schmidt, P., Daly, R., Bloch, M., Smith, M., Danaceau, M., Simpson, 
L.,…Rubinow, D. (2005). Dehydroepiandrosterone monotherapy in 
midlife-onset major and minor depression. Archives of General 
Psychiatry, 62, 154-162. https://dx.doi.org/10.1001/archpsyc.62.2.154
Slawson, D. (2018). DHEA effective for midlife-onset depression. American 
Family Physician, 71(11), 2173-2174. Retrieved from: 
http://www.aafp.org/afp/2005/0601/p2173a.html
